Acquired Hemophilia Treatment Market Size, Market Competition by Company, Country, Application/Type & Forecast to 2025
The global acquired hemophilia treatment market is set to
reach USD 2,700.9 million by 2025, growing at a CAGR of 3.1%. The clinical
manifestation associated with acquired hemophilia is provoked or spontaneous
unexplained bleeding with delayed activated partial thromboplastin time (aPTT)
in patients with no previous hereditary association with coagulopathy.
Researchers throughut the globe are actively enaged in developing guidelines
for the accurate diagnosis of acquired hemophilia due to its overlapping
clinical manifestations with other autoimmune disease. The exorbitant cost
associated with the bypassing agents employed as hemostatic therapy to control
bleeding episodes will hamper the acquired hemophilia treatment market growth.
Get Sample Copy of this Report: https://www.adroitmarketresearch.com/contacts/request-sample/1037
North America is currently dominating the regional segment
for acquired hemophilia treatment market. The key parameters responsible for
its supreme market growth are rising public health awarness regarding
autoimmune disease leading to early disease diagnosis and treatment. As per the
latest research findings brought forward by the Center for Disease Control and
Prevention (CDC), the prevalence rate of acquired hemophilia in the United
States is 0.2 to 1 per million people. Affordable reimbursement scenario for
medicines employed for treating acquired hemophilia in federally funded
hemophilia care centers will further strenghten the market growth in the
region. Europe represents 31.8% market share on account of presene of key
players such as Baxter Healthcare Corporation, Shire, Plc., Novo Nordisk and
GlxoSmithkline, Plc., wich determines the market growth in the region. Asia
Pacific holds 16.4% market share and is keen to register rampant growth during
the forecast period on account of rising prevalence of acquired hemophilia in
elderly population and developing healthcare infrastructure.
ACCESS FULL REPORT: https://www.adroitmarketresearch.com/industry-reports/acquired-hemophilia-treatment-market
The key biopharmaceutical companies actively engaged in the manufacturing of drugs
employed for the treatment of acquired hemophilia are Baxter Healthcare
Corporation, BioXcel Corporation, Genetech, Inc., GlaxoSmithkline, Plc.,
Ferring B.V., Mylan N.V., Novo Nordisk, Sanofi SA, Shire, Plc. and Teva
Pharmaceutical Industries Ltd.
Any Questions? Feel Free to Enquire Here. We will Put
You on The Right @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/1037
About Us:
Adroit Market Research is a global business analytics and
consulting company incorporated in 2018. Our target audience is a wide range of
corporations, manufacturing companies, product/technology development
institutions and industry associations that require understanding of a market’s
size, key trends, participants and future outlook of an industry. We intend to
become our clients’ knowledge partner and provide them with valuable market
insights to help create opportunities that increase their revenues. We follow a
code– Explore, Learn and Transform. At our core, we are curious people who love
to identify and understand industry patterns, create an insightful study around
our findings and churn out money-making roadmaps.
Contact Us:
Ryan Johnson
Account Manager - Global
3131 McKinney Ave Ste 600
Dallas, TX 75204
Email ID: sales@adroitmarketresearch.com
Phone No.: +1 972-362 -8199
Comments
Post a Comment